急性心筋梗塞後の心不全結果に対するエンパグリフロジンの影響:EMPACT- MI試験からの洞察
PubMedで要約を見る
まとめ
この要約は機械生成です。エムパグリフロジンは,急性心筋梗塞後の心不全の入院を著しく減少させた. このSGLT2阻害剤は,高リスク患者の初発症および全発症の減少に効果を示した.
科学分野
- 心臓病科
- 薬理学について
- 内分泌学
背景
- エムパグリフロジンは,2型糖尿病患者の心不全 (HF) の発生を軽減することが知られている.
- EMPACT- MI試験では,心筋梗塞 (MI) の後のHFと死亡率に対するエンパグリフロジンの効果を調査した.
- MI後の最初のおよび再発したHF事件に対するempagliflozinの影響は,以前は不明でした.
研究 の 目的
- 急性心筋梗塞後の心不全を軽減するエンパグリフロジンの有効性を評価する.
- エムパグリフロジンが,心筋梗塞後,エジェクション分数または血圧が低下した患者の初回の入院および総入院に及ぼす効果を分析する.
主な方法
- 急性心筋梗塞で入院した患者6522人を対象とした,ランダム化,プラセボ対照試験 (EMPACT- MI).
- 患者は,入院後14日以内にエムパグリフロジン10mgまたはプラセボを投与された.
- 予め指定された二次分析は,最初の入院および全院入院を含むHFのアウトカムに焦点を当てた.
主要な成果
- エムパグリフロジンは,最初のHF入院のリスク (HR 0. 77,P=0. 031) と17. 9ヶ月間のHF入院の総リスク (RR 0. 67,P=0. 006) を有意に減少させた.
- 臨床的に重要な患者のサブグループにおいて,利益は一貫していた.
- エムパグリフロジンを投与した患者のうち,退院後に新たな利尿薬,レニン- 血管新生調節薬,またはミネラルコルチコイド受容体抗体が必要になった患者は少なくなった.
結論
- エムパグリフロジンは,急性心筋梗塞の後に左心室機能障害または閉塞を有する患者の心不全の入院リスクを効果的に軽減します.
- 心臓発作後の心不全のリスクのある患者の治療にエンパグリフロジンの使用は支持されています.
関連する概念動画
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

